 |
|
Zonisamide for Weight Loss in Obese Adults
A Randomized Controlled Trial
Kishore M. Gadde, MD;
Deborah M. Franciscy, MS, RD;
H. Ryan Wagner, II, PhD;
K. Ranga R. Krishnan, MD
JAMA. 2003;289:1820-1825.
Context Zonisamide is a marketed antiepileptic drug that has serotonergic and dopaminergic activity in addition to blockade of sodium and calcium channels. Weight loss was an adverse effect associated with zonisamide treatment in epilepsy clinical trials.
Objective To evaluate the efficacy of zonisamide for weight loss in obese adults.
Design and Setting Sixteen-week randomized, double-blind, placebo-controlled trial with an optional single-blind extension of the same treatment for another 16 weeks, conducted at Duke University Medical Center from March 2001 to March 2002.
Participants Fifty-five (92%) women and 5 (8%) men (mean [SE] body mass index, 36.3 [0.5]; mean age, 37.0 (1.0) years).
Interventions Patients were randomly assigned to receive zonisamide (n = 30) or placebo (n = 30). All participants were prescribed a balanced hypocaloric diet (500 kcal/d deficit) and compliance was monitored with self-rated food diaries. Zonisamide therapy was started at 100 mg/d orally, with gradual increase to 400 mg/d and further increase to 600 mg/d for patients losing less than 5% of body weight at the end of 12 weeks. Placebo dosing was identical.
Main Outcome Measure Change in body weight.
Results Of the 60 randomized patients, 51 completed the 16-week acute phase. In an intent-to-treat analysis using the available data for all randomized participants with the last observation carried forward, the zonisamide group lost more body weight than the placebo group (mean [SE], 5.9 [0.8] kg [6.0% loss] vs 0.9 [0.4] kg [1.0% loss]; t = 5.5; P<.001) during the 16-week period. A longitudinal mixed-model regression for weight change controlling for age, race, sex, body mass index, and percent body fat estimated that zonisamide treatment over the 16-week study duration was associated with significantly greater weight loss than was placebo (t = 6.4; P<.001). Seventeen (57%) of 30 in the zonisamide group and 3 (10%) of 30 in the placebo group lost at least 5% of body weight (P<.001) by week 16. Of the 37 participants who entered the extension phase, 36 completed week 32. The zonisamide group (n = 19) had a mean weight loss of 9.2 kg (1.7 kg) (9.4% loss) at week 32 compared with 1.5 kg (0.7 kg) (1.8% loss) for the placebo group (n = 17) (t = 4.0; P<.001). Zonisamide was tolerated well, with few adverse effects.
Conclusion In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity.
Author Affiliations: Obesity Clinical Trials Program, Department of Psychiatry, Duke University Medical Center, Durham, NC.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Weight-Loss Pharmacotherapy: A Brief Review
Huizinga
Clin. Diabetes 2007;25:135-140.
ABSTRACT
| FULL TEXT
Pharmacotherapeutic Options for Overweight Adolescents
Dunican et al.
The Annals of Pharmacotherapy 2007;41:1445-1455.
ABSTRACT
| FULL TEXT
Pharmacological Treatment of the Overweight Patient
Bray and Greenway
Pharmacol. Rev. 2007;59:151-184.
FULL TEXT
Optimizing therapy of seizures in patients with endocrine disorders
Steinhoff
Neurology 2006;67:S23-S27.
ABSTRACT
| FULL TEXT
Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Gadde and Allison
Circulation 2006;114:974-984.
FULL TEXT
Review: Pharmacological approaches to reduce adiposity
Day and Bailey
British Journal of Diabetes & Vascular Disease 2006;6:121-125.
ABSTRACT
Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians
Snow et al.
ANN INTERN MED 2005;142:525-531.
ABSTRACT
| FULL TEXT
Meta-Analysis: Pharmacologic Treatment of Obesity
Li et al.
ANN INTERN MED 2005;142:532-546.
ABSTRACT
| FULL TEXT
Antiepileptic drugs in psychiatry
Ovsiew
J. Neurol. Neurosurg. Psychiatry 2004;75:1655-1661.
FULL TEXT
Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues
Sankar
Neurology 2004;63:S30-S39.
ABSTRACT
| FULL TEXT
Pharmacological Approaches to Weight Reduction: Therapeutic Targets
Korner and Aronne
J. Clin. Endocrinol. Metab. 2004;89:2616-2621.
FULL TEXT
Hypertension and Obesity
Aneja et al.
Recent Prog Horm Res 2004;59:169-205.
ABSTRACT
| FULL TEXT
Treating Obesity: New Directions
JWatch Psychiatry 2003;2003:2-2.
FULL TEXT
News About Obesity from JAMA
JWatch General 2003;2003:6-6.
FULL TEXT
|
